The concept of using albuminuria as a surrogate marker for CKD progression and CVD outcomes is widely accepted, with the reduction of urine albumin levels often being regarded as a target for therapy.27,28 Many studies have shown that ACEIs and ARBs can reduce urine protein levels, which is considered to be independent of their kidney protection function, separate from antihypertension. This evidence concerns the gene ALB and chronic kidney disease.